Maribavir is not recommended to be co-administered with valganciclovir/ganciclovir.
- Trade Name: Livtencity (Takeda)
- Indications: Treatment of cytomegalovirus disease/infection.
- Half-life: 4 hours
- FDA Approval Date: 11/23/2021
- Clinically important, potentially hazardous interactions with:
Carbamazepine, Cyclosporine, CYP3A4 inducers, Digoxin, Everolimus, Phenobarbital, Phenytoin, Rifabutin, Rifampin, Rosuvastatin, Sirolimus, St John's Wort, Tacrolimus - Pregnancy: No adequate human data currently available to establish if there is a risk to pregnancy outcomes.
Please login to view the rest of this drug profile.
Page last updated 08/20/2025
